

WEST Search History

DATE: Sunday, September 08, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
L16	L15 and parenteral\$	2594	L16
L15	L14 and bioavail\$	3453	L15
L14	L13 and ((milk produc\$) or lact\$)	24279	L14
L13	L12 and (extend\$ or sustain\$ or prolong\$)	24354	L13
L12	L10 and ((zinc salt?) or (zinc complex\$))	39749	L12
L11	L10 and ((zinc salt?) or (zinc complex\$))	39749	L11
L10	L8 and (human or porcine or bovine or equine)	43444	L10
L9	l5 and (histidine\$ or polyhistidine or arginine or lysine or tryptophan or glycine or suberoxam\$ or (salicyl hydroxam\$) or bufexam\$ or caprylohydroxam\$ or (monobasic potassium phosphate) or (dibasic potassium phosphate) or (monobasic calcium phosphate) or (dibasic calcium phosphate) or (sodium nitrate) (dibasic sodium sulfate) or (phosphate salt?) or (nitrate salt?) or (sulfate salt?))	63559	L9
L8	L7 and (nonaqueous or (Non aqueous))	61133	L8
L7	L6 and ((polyoxyethylene 4 stearate) or (polyoxyethylene 8 stearate) or (polyoxyethylene(w)20 sorbitan monooleate) or (tween 80) or (hydroxypropyl beta cyclodextrin))	63509	L7
L6	L5 and (histidine\$ or polyhistidine or arginine or lysine or tryptophan or glycine or suberohydroxam\$ or (salicyl hydroxam\$) or bufexam\$ or caprylohydroxam\$ or (monobasic potassium phosphate) or (dibasic potassium phosphate) or (monobasic calcium phosphate) or (dibasic calcium phosphate) or (sodium nitrate) or (dibasic sodium sulfate) or (phosphate salt?) or (nitrate salt?) or (sulfate salt?))	63559	L6
L5	L4 and (polyol or (carbohydrate ester?) or trehalose\$ or sucrose\$ or mannitol or sorbitol or (cellobiose octaacetate))	66082	L5
L4	L3 and ((nonreducing carbohydrate) or (amino acid\$) or hydroxam\$ or oxoacid\$)	86734	L4
L3	L2 and ((tocopherol polyethylene) or (sugar fatty) or (polyoxyethylene glyceride) or (polyoxyethylene vegetable))	90917	L3
L2	L1 and ((nonionic surfactant) or cyclodextrin or (polyoxyethylene fatty) or poloxamer or (polyoxyethylene sorbitan))	108774	L2
L1	somatotropin or gh or hGH or (human growth hormone) or (growth hormone)	999239	L1

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 14:07:28 ON 08 SEP 2002)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 14:08:01 ON 08 SEP 2002

L1 217623 S (SOMATOTROPIN OR GH OR HGH OR (HUMAN GROWTH HORMONE) OR (GROW
L2 7301 S L1 AND ((NONIONIC SURFACTANT) OR CYCLODEXTRIN OR (POLYOXYETHY
L3 191 S L2 AND (NONAQUEOUS? OR NON(W)AGUEOUS)
L4 111 S L3 AND (HUMAN OR PORCINE OR BOVINE OR EQUINE)
L5 4 S L4 AND (ZINC(W)SALT# OR ZINC(W)COMPLEX?)
L6 90 S L4 AND (NONREDUCING(W)CARBOHYDRATE OR AMINO(W)ACID? OR HYDRO
L7 73 S L6 AND (TREHALOSE OR SUCROSE OR MANNITOL OR SORBITOL OR TREH
L8 52 S L7 AND (HISTIDINE? OR POLYHISTIDINE OR ARGININE OR LYSINE OR
L9 6 S L8 AND ((SODIUM NITRATE) OR (DIBASIC SODIUM SULFATE) OR (PHO
L10 29 S L8 AND ((POLYOXYETHYLENE 4 STEARATE) OR (POLYOXYETHYLENE 8 S
L11 2 S L10 AND (EXTEND? OR SUSTAIN?) (W)RELEASE

d 118 1-11 ibib ab

L18 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:10312 CAPLUS
DOCUMENT NUMBER: 136:74655
TITLE: Non-aqueous surfactant-containing formulations for
extended release of **somatotropin**
INVENTOR(S): Jeng, Yunhua N.; Patel, Kanaiyalal R.
PATENT ASSIGNEE(S): Monsanto Technology LLC, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000261	A2	20020103	WO 2001-US20345	20010626
WO 2002000261	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001071491	A5	20020108	AU 2001-71491	20010626
US 2002068693	A1	20020606	US 2001-891445	20010626
PRIORITY APPLN. INFO.:			US 2000-214168P P	20000626
			WO 2001-US20345 W	20010626

AB The present invention provides compns. comprising biol.-active **somatotropin** formulated for extended release and methods of prep. and methods of using the same. These compns. comprise **somatotropin**, at least a first bioavailability-enhancing constituent (BEC), and a substantially non-aq., hydrophobic excipient, and optionally a second BEC. The first BEC is typically a surfactant (preferably a non-ionic surfactant) or a cyclodextrin compd. The optional second BEC may comprise (i) amino acids or amino acid derivs.; (ii) hydroxamate derivs.; (iii) non-reducing carbohydrates; (iv) oxo-acid salts; or (v) a mixt. of two or more compds. from within the foregoing classes (i)-(iv). A pharmaceutical compn. contained Tween 80 1, monobasic sodium phosphate:dibasic sodium phosphate (4:6) 5, zinc **somatotropin** 38, and sesame oil:aluminum monostearate (95:5) q.s. 100%.

L18 ANSWER 2 OF 11 USPATFULL
ACCESSION NUMBER: 2002:224605 USPATFULL
TITLE: Lipid soluble steroid prodrugs
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
PATENT ASSIGNEE(S): Shen, DeKang, Tucson, AZ, United States
Imarx Therapeutics, Inc., Tucson, AZ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444660	B1	20020903
APPLICATION INFO.:	US 2000-496761		20000203 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-851780, filed on 6 May 1997, now patented, Pat. No. US 6090800		
DOCUMENT TYPE:	Utility		

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Badio, Barbara P.
LEGAL REPRESENTATIVE: Woodcock Washburn LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 6452
AB The present invention is directed to novel lipid soluble steroid prodrugs, compositions comprising steroid prodrugs, and uses of the same.

L18 ANSWER 3 OF 11 USPATFULL
ACCESSION NUMBER: 2002:133835 USPATFULL
TITLE: Non-aqueous surfactant-containing formulations for extended release of **somatotropin**
INVENTOR(S): Jeng, Yunhua N., Chesterfield, MO, UNITED STATES
Patel, Kanaiyalal R., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068693	A1	20020606
APPLICATION INFO.:	US 2001-891445	A1	20010626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214168P	20000626 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOWREY SIMON ARNOLD & WHITE, 750 BERING DRIVE, HOUSTON, TX, 77057-2198
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1394

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising biologically-active **somatotropin** formulated for extended release and methods of preparing and methods of using the same. These compositions comprise **somatotropin**, at least a first bioavailability-enhancing constituent (BEC), and a substantially non-aqueous, hydrophobic excipient, and optionally a second BEC. The first BEC is typically a surfactant (preferably a non-ionic surfactant) or a **cyclodextrin** compound. The optional second BEC may comprise (i) **amino acids** or **amino acid** derivatives; (ii) **hydroxamate** derivatives; (iii) non-reducing carbohydrates; (iv) oxo-acid salts; or (v) a mixture of two or more compounds from within the foregoing classes (i)-(iv).

L18 ANSWER 4 OF 11 USPATFULL
ACCESSION NUMBER: 2002:78737 USPATFULL
TITLE: Cobalamin compounds useful as antibiotic agents and as imaging agents
INVENTOR(S): Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
Collins, Douglas A., Rochester, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042394	A1	20020411
APPLICATION INFO.:	US 2001-873164	A1	20010531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208148P	20000531 (60)
	US 2001-267543P	20010209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA,
GA, 30303-1763

NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 4896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a microbial infection.

L18 ANSWER 5 OF 11 USPATFULL

ACCESSION NUMBER: 2002:69629 USPATFULL
TITLE: Self-destructing, controlled release peroral drug delivery system
INVENTOR(S): Ritschel, Wolfgang A., Cincinnati, OH, United States
Agrawal, Mukul A., Strongsville, OH, United States
PATENT ASSIGNEE(S): University of Cincinnati, Cincinnati, OH, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6365185	B1	20020402
APPLICATION INFO.:	US 1999-277258		19990326 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79403P	19980326 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Tran, S.	
LEGAL REPRESENTATIVE:	Wood, Herron & Evans, LLP	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 15 Drawing Page(s)	
LINE COUNT:	2031	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to tablets which are time-controlled to release active agent at different rates in different regions of the digestive tract in order to maintain a substantially constant concentration in the blood. In one embodiment, a new modified release drug delivery system, for once a day peroral use, consisting of a solid core comprising an active agent together with a hydrogel, with the solid core being coated with a semi-permeable, self-destructing membrane which is optionally drilled to provide a release orifice, and then optionally further coated with the same or different active agent material. The device delivers the active agent in a substantially constant effective dose for the duration of the transit through the stomach and small intestine, followed by accelerated release when reaching the large intestine.

L18 ANSWER 6 OF 11 USPATFULL

ACCESSION NUMBER: 2002:67175 USPATFULL
TITLE: Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
INVENTOR(S): Wilson, Leland F., Menlo Park, CA, UNITED STATES
Doherty, Paul C., JR., Cupertino, CA, UNITED STATES
Place, Virgil A., Kawaihae, HI, UNITED STATES
Smith, William L., Montclair, NJ, UNITED STATES
Abdel-Hamid Abdou Ali, Ibrahim AbouBakr, Mansoura,

EGYPT

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037828	A1	20020328
	US 6403597	B2	20020611
APPLICATION INFO.:	US 2001-888250	A1	20010621 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-467094, filed on 10 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-181070, filed on 27 Oct 1998, GRANTED, Pat. No. US 6037346 Continuation-in-part of Ser. No. US 1997-958816, filed on 28 Oct 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	94		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2011		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.		

L18 ANSWER 7 OF 11 USPATFULL

ACCESSION NUMBER:	2002:32536 USPATFULL
TITLE:	Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
INVENTOR(S):	Manthorpe, Marston, San Diego, CA, UNITED STATES Hartikka, Jukka, San Diego, CA, UNITED STATES Sukhu, Loretta, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S):	Vical Incorporated, San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019358	A1	20020214
APPLICATION INFO.:	US 2001-839574	A1	20010423 (9)
PRIORITY INFORMATION:	US 2000-198823P		20000421 (60)
	US 2000-253153P		20001128 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934		
NUMBER OF CLAIMS:	163		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Page(s)		
LINE COUNT:	4605		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.		

L18 ANSWER 8 OF 11 USPATFULL

ACCESSION NUMBER: 2001:217985 USPATFULL
TITLE: Infrared thermography and methods of use
INVENTOR(S): Marek, Przemyslaw A., Bolton, MA, United States
Trocha, Andzrej M., Billerica, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001046471	A1	20011129
APPLICATION INFO.:	US 2001-850081	A1	20010508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-202935P	20000509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	99	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2687	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes rapid noninvasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises the administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent to the patient followed by monitoring the temperature change of an area of interest using infrared thermography. The present invention provides methods for diagnosing diseases or disorders related to vasodilation and changes in blood flow, such as, sexual dysfunction, Raynaud's syndrome, inflammation, hypertension, gastrointestinal disorders and central nervous system disorders. The sexual dysfunction is preferably female sexual dysfunction and female sexual arousal. The vasoactive agents include potassium channel activators, calcium channel blockers, .alpha.-adrenergic receptor antagonists, .beta.-blockers, phosphodiesterase inhibitors, adenosine, ergot alkaloids, vasoactive intestinal peptides, prostaglandins, dopamine agonists, opioid antagonists, endothelin antagonists and thromboxane inhibitors. The present invention can also be used to screen and identify drug candidates for treating diseases, disorders and conditions resulting from vasodilation or changes in blood flow. The present invention also describes compositions comprising at least one S-nitrosothiol compound for diagnosing, monitoring and/or treating female sexual dysfunctions.

L18 ANSWER 9 OF 11 USPATFULL

ACCESSION NUMBER: 2000:174129 USPATFULL
TITLE: Preparation for the application of agents in mini-droplets
INVENTOR(S): Cevc, Gregor, Heimstetten, Germany, Federal Republic of
PATENT ASSIGNEE(S): Idea AG, Munich, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6165500		20001226
APPLICATION INFO.:	US 1992-844664		19920408 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4026834 DE 1990-4026833 DE 1991-4107153 WO 1991-EP1596	19900824 19900824 19910306 19910822
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kishore, Gollamudi S.	
LEGAL REPRESENTATIVE:	Davidson, Davidson & Kappel, LLC	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	4336	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.

L18 ANSWER 10 OF 11 USPATFULL
 ACCESSION NUMBER: 2000:91955 USPATFULL
 TITLE: Lipid soluble steroid prodrugs
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Shen, DeKang, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., Tucson, AZ, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6090800		20000718
APPLICATION INFO.:	US 1997-851780		19970506 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Badio, Barbara		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6285		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel lipid soluble steroid prodrugs compositions comprising steroid prodrugs, and uses of the same.

L18 ANSWER 11 OF 11 EUROPATFULL COPYRIGHT 2002 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1132405 EUROPATFULL EW 200137 FS OS STA R
 TITLE: NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN, ITS DNA AND
 LIGAND THEREOF.
 NEUARTIGES G-PROTEIN GEKOPPELTES REZEPTORPROTEIN, DESSEN
 DNA UND LIGAND.
 NOUVELLE PROTEINE RECEPTEUR COUPLEE A LA PROTEINE G,
 SON ADN ET SON LIGAND.

INVENTOR(S) : WATANABE, Takuya, 14-9-B904, Niitaka 6-chome,
 Yodogawa-ku, Osaka-shi, Osaka 532-0033, JP;
 KIKUCHI, Kuniko, Sanhaisu 101, 8-18, Shinmachi 5-chome,
 Toride-shi, Ibaraki 302-0024, JP;
 TERAO, Yasuko, Royal Zoa Nakayama 307, Oaza Onozaki 985,
 Tsukuba-shi, Ibaraki 305-0034, JP;
 SHINTANI, Yasushi, Takeda Kasuga Haitsu 703, 7-9, Kasuga
 1-chome, Tsukuba-shi, Ibaraki 305-0821, JP;
 HINUMA, Shuji, Takeda Kasuga Haitsu 1402, 7-9, Kasuga
 1-chome, Tsukuba-shi, Ibaraki 305-0821, JP;
 FUKUSUMI, Shoji, Royal City Namiki 302, 17-6, Namiki
 3-chome, Tsukuba-shi, Ibaraki 305-0044, JP;
 FUJII, Ryo, Takeda Kasuga Haitsu 303, 7-9, Kasuga
 1-chome, Tsukuba-shi, Ibaraki 305-0821, JP;
 HOSOYA, Masaki, 711-83, Itaya 1-chome, Tsuchiura-shi,
 Ibaraki 300-0007, JP;
 KITADA, Chieko, 2-8, Minamikyocho 1-cho, Sakai-shi,
 Osaka 590-0073, JP

PATENT ASSIGNEE(S) : Takeda Chemical Industries, Ltd., 1-1 Doshomachi
 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, JP

PATENT ASSIGNEE NO: 204702

AGENT: Keller, Guenter, Dr. et al., Lederer, Keller & Riederer
 Patentanwaelte Prinzregentenstrasse 16, 80538 Muenchen,
 DE

AGENT NUMBER: 59792

OTHER SOURCE: BEPA2001072 EP 1132405 A1 0078

SOURCE: Wila-EPZ-2001-H37-T1a

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R
 GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R
 SE; R AL; R LT; R LV; R MK; R RO; R SI

PATENT INFO. PUB. TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale
 Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND DATE
'OFFENLEGUNGS' DATE:	EP 1132405	A1 20010912
APPLICATION INFO.:	EP 1999-972224	20010912
PRIORITY APPLN. INFO.:	JP 1998-323759	19981111
	JP 1999-60030	19990308
	JP 1999-106812	19990414
	JP 1999-166672	19990614
	JP 1999-221640	19990804
	JP 1999-259818	19990914
RELATED DOC. INFO.:	WO 99-JP6283	991111 INTAKZ
	WO 0029441	000525 INTPNR

ABEN The present invention relates to a novel polypeptide, its partial
 peptide or salt thereof, a method for manufacturing the polypeptide, a
 receptor of the polypeptide, a pharmaceutical composition comprising the
 polypeptide or the like, an antibody to the polypeptide, a method/kit
 for screening a compound that promotes or inhibits an activity of the
 polypeptide or salt thereof, a compound that can be obtained by the
 screening, a pharmaceutical composition comprising the compound, and the
 like.

The polypeptide, its partial peptide or the like of the present
 invention can be used, for example, as a therapeutic agent for nervous
 disease, a promoting agent for somatostatin secretion and the like.
 Further, the antibody of the present invention can be used for a
 quantification of the polypeptide of the present invention in a sample
 solution. Furthermore, the polypeptide of the present invention is

useful for a reagent for screening a compound that promotes or inhibits the activity of the polypeptide of the present invention.

=>

=> d his

(FILE 'HOME' ENTERED AT 14:07:28 ON 08 SEP 2002)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 14:08:01 ON 08 SEP 2002

L1 217623 S (SOMATOTROPIN OR GH OR HGH OR (HUMAN GROWTH HORMONE) OR (GROW
L2 7301 S L1 AND ((NONIONIC SURFACTANT) OR CYCLODEXTRIN OR (POLYOXYETHY
L3 191 S L2 AND (NONAQUEOUS? OR NON(W)AGUEOUS)
L4 111 S L3 AND (HUMAN OR PORCINE OR BOVINE OR EQUINE)
L5 4 S L4 AND (ZINC(W) SALT# OR ZINC(W) COMPLEX?)
L6 90 S L4 AND (NONREDUCING(W) CARBOHYDRATE OR AMINO(W) ACID? OR HYDRO
L7 73 S L6 AND (TREHALOSE OR SUCROSE OR MANNITOL OR SORBITOL OR TREH
L8 52 S L7 AND (HISTIDINE? OR POLYHISTIDINE OR ARGININE OR LYSINE OR
L9 6 S L8 AND ((SODIUM NITRATE) OR (DIBASIC SODIUM SULFATE) OR (PHO
L10 29 S L8 AND ((POLYOXYETHYLENE 4 STEARATE) OR (POLYOXYETHYLENE 8 S
L11 2 S L10 AND (EXTEND? OR SUSTAIN?) (W) RELEASE
L12 2859 S L2 AND (HUMAN OR PORCINE OR BOVINE OR EQUINE)
L13 1789 S L12 AND (NONREDUCING(W) CARBOHYDRATE OR AMINO(W) ACID? OR HYDRO
L14 1460 S L13 AND (TREHALOSE OR SUCROSE OR MANNITOL OR SORBITOL OR TRE
L15 827 S L14 AND (HISTIDINE? OR POLYHISTIDINE OR ARGININE OR LYSINE O
L16 54 S L15 AND ((SODIUM NITRATE) OR (DIBASIC SODIUM SULFATE) OR (PH
L17 17 S L16 AND ((POLYOXYETHYLENE 4 STEARATE) OR (POLYOXYETHYLENE 8
L18 11 S L17 AND (SUSTAIN? OR EXTENDED OR PROLONG?)

=>

L18 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:10312 CAPLUS
DOCUMENT NUMBER: 136:74655
TITLE: Non-aqueous surfactant-containing formulations for
extended release of **somatotropin**
INVENTOR(S): Jeng, Yunhua N.; Patel, Kanaiyalal R.
PATENT ASSIGNEE(S): Monsanto Technology LLC, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000261	A2	20020103	WO 2001-US20345	20010626
WO 2002000261	A3	20020606		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001071491	A5	20020108	AU 2001-71491	20010626
US 2002068693	A1	20020606	US 2001-891445	20010626
PRIORITY APPLN. INFO.:			US 2000-214168P	P 20000626
			WO 2001-US20345	W 20010626